Revance Therapeutics Inc (FRA:RTI)
€ 3.4 -0.1 (-2.86%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection Call Transcript

Sep 08, 2022 / 12:00PM GMT
Release Date Price: €22.8 (+10.68%)
Operator

Good morning, and welcome to the Revance conference call. (Operator Instructions)

As a reminder, this call is being recorded today, September 8, 2022. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance. Please go ahead.

Jessica Serra
Revance Therapeutics, Inc. - Head of IR & ESG

Thank you, Olivia. Good morning, everyone, and thank you for joining our conference call to discuss the U.S. FDA approval of DAXXIFY, a brand name for daxibotulinumtoxinA-lanm injection. Joining us are Chief Executive Officer, Mark Foley; President, Dustin Sjuts and Chief Financial Officer, Tobin Schilke.

The press release announcement and approval issued earlier today is available on our corporate website and contains the indication statement for DAXXIFY as well as important safety information. The product label and full U.S. prescribing information for DAXXIFY are also available on our website.

During this conference call, management will make forward-looking statements, including

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot